Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)
33.83
-0.81 (-2.34%)
Apr 9, 2026, 3:00 PM CST
SHA:600976 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 113.71 | 163.17 | 305.12 | 219.33 | 301.66 |
Short-Term Investments | 136.51 | - | - | - | - |
Trading Asset Securities | 954.14 | 954.19 | 694.46 | 641.38 | 538.63 |
Cash & Short-Term Investments | 1,204 | 1,117 | 999.58 | 860.71 | 840.28 |
Cash Growth | 7.79% | 11.78% | 16.13% | 2.43% | 45.64% |
Accounts Receivable | 1,040 | 957.56 | 1,150 | 868.66 | 674.6 |
Other Receivables | 123.8 | 25.76 | 31.43 | 49.64 | 21.43 |
Receivables | 1,164 | 983.33 | 1,181 | 918.29 | 696.03 |
Inventory | 286.57 | 354.31 | 450.85 | 362.88 | 222.6 |
Other Current Assets | 94.89 | 146.43 | 134.06 | 162.85 | 104.5 |
Total Current Assets | 2,750 | 2,601 | 2,766 | 2,305 | 1,863 |
Property, Plant & Equipment | 698.07 | 595.59 | 450.7 | 417.65 | 396.65 |
Long-Term Investments | 722.3 | 772.18 | 650.42 | 444.94 | 326.85 |
Goodwill | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 |
Other Intangible Assets | 27.53 | 28.19 | 28.87 | 31.16 | 32.98 |
Long-Term Deferred Tax Assets | 180.34 | 129.49 | 139.44 | 117.27 | 118.33 |
Long-Term Deferred Charges | 136.33 | 130.78 | 111.27 | 91.66 | 87.64 |
Other Long-Term Assets | 12.16 | 19.74 | 21.14 | 32.56 | 30.01 |
Total Assets | 4,527 | 4,278 | 4,168 | 3,440 | 2,856 |
Accounts Payable | 642.52 | 742.22 | 782.91 | 611.06 | 374.92 |
Accrued Expenses | 716.3 | 574.78 | 724.73 | 620.32 | 592.57 |
Short-Term Debt | 55.05 | 140.9 | 79.45 | 22.52 | 45 |
Current Portion of Leases | 5.62 | 6.39 | 5.12 | 7.34 | 6.1 |
Current Income Taxes Payable | 104.05 | 52.74 | 66.23 | 49.68 | 71.75 |
Current Unearned Revenue | 36.19 | 61.43 | 41.19 | 82.52 | 37.04 |
Other Current Liabilities | 176.11 | 166.66 | 157.31 | 140.25 | 191.85 |
Total Current Liabilities | 1,736 | 1,745 | 1,857 | 1,534 | 1,319 |
Long-Term Debt | 34.03 | 4 | - | - | - |
Long-Term Leases | 31.03 | 24.43 | 30.29 | 23.48 | 20.37 |
Long-Term Unearned Revenue | 44.41 | 46.55 | 18.61 | 12.18 | 27.72 |
Long-Term Deferred Tax Liabilities | 4.8 | 7.2 | 5.62 | 5.97 | 0.84 |
Total Liabilities | 1,850 | 1,827 | 1,911 | 1,575 | 1,368 |
Common Stock | 153.4 | 153.4 | 153.4 | 153.4 | 153.4 |
Additional Paid-In Capital | 522.73 | 523.42 | 520.68 | 509.17 | 421.5 |
Retained Earnings | 1,980 | 1,758 | 1,580 | 1,212 | 931.06 |
Treasury Stock | - | - | -6.76 | -14.99 | -25.08 |
Total Common Equity | 2,656 | 2,435 | 2,248 | 1,860 | 1,481 |
Minority Interest | 20.4 | 15.03 | 8.78 | 4.99 | 7.04 |
Shareholders' Equity | 2,677 | 2,450 | 2,256 | 1,865 | 1,488 |
Total Liabilities & Equity | 4,527 | 4,278 | 4,168 | 3,440 | 2,856 |
Total Debt | 125.73 | 175.71 | 114.86 | 53.34 | 71.48 |
Net Cash (Debt) | 1,079 | 941.65 | 884.72 | 807.37 | 768.81 |
Net Cash Growth | 14.55% | 6.44% | 9.58% | 5.02% | 38.07% |
Net Cash Per Share | 7.10 | 6.19 | 5.79 | 5.30 | 5.06 |
Filing Date Shares Outstanding | 153.4 | 153.4 | 153.82 | 152.78 | 151.97 |
Total Common Shares Outstanding | 153.4 | 153.4 | 153.82 | 152.78 | 151.97 |
Working Capital | 1,014 | 856.33 | 908.95 | 771.06 | 544.18 |
Book Value Per Share | 17.32 | 15.88 | 14.61 | 12.17 | 9.74 |
Tangible Book Value | 2,629 | 2,407 | 2,219 | 1,829 | 1,448 |
Tangible Book Value Per Share | 17.14 | 15.69 | 14.42 | 11.97 | 9.53 |
Buildings | 409.52 | 287.12 | 284.12 | 289.38 | 298.05 |
Machinery | 485.88 | 314.22 | 312.36 | 301.9 | 251.25 |
Construction In Progress | 40.17 | 206.68 | 41.48 | 17.19 | 16.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.